Important November 30, 2010 Class Action Deadline Approaching for AspenBio Pharma Shareholders, Says the Rosen Law Firm -- APPY


NEW YORK, Nov. 25, 2010 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds investors of the important November 30, 2010 lead plaintiff deadline in the class action filed on behalf of investors who purchased the common stock of AspenBio Pharma, Inc. ("AspenBio" or the "Company") (Nasdaq:APPY) between February 22, 2007 and July 19, 2010, inclusive (the "Class Period").

To join the AspenBio class action, visit the firm's website at www.rosenlegal.com/" target="_top" rel="nofollow">http://www.rosenlegal.com, or call Laurence Rosen, Esq. or Phillip Kim, Esq., toll-free, at 866-767-3653; you may also email www.globenewswire.com/newsroom/ctr%3Fd=202816%26l=2%26a=lrosen%2540rosenlegal.com%26u=mailto%253Alrosen%2540rosenlegal.com">lrosen@rosenlegal.com or www.globenewswire.com/newsroom/ctr%3Fd=202816%26l=2%26a=pkim%2540rosenlegal.com%26u=mailto%253Apkim%2540rosenlegal.com">pkim@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

The Complaint asserts violations of the federal securities laws against AspenBio and certain of its officers and directors for issuing materially false and misleading statements about the effectiveness of AppyScore as a test to diagnose appendicitis. According to the Complaint, Defendants were aware or recklessly disregarded information that AppyScore was not effective in detecting appendicitis as it could not differentiate between appendicitis and other medical conditions. According to the Complaint, this adverse information caused the Company's stock to drop, causing investors substantial losses.

If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2010. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Laurence Rosen, Esq. or Phillip Kim, Esq. of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at www.globenewswire.com/newsroom/ctr%3Fd=202816%26l=5%26a=lrosen%2540rosenlegal.com%26u=mailto%253Alrosen%2540rosenlegal.com">lrosen@rosenlegal.com or www.globenewswire.com/newsroom/ctr%3Fd=202816%26l=5%26a=pkim%2540rosenlegal.com%26u=mailto%253Apkim%2540rosenlegal.com">pkim@rosenlegal.com. You may also visit the firm's website at www.rosenlegal.com/" target="_top" rel="nofollow">http://www.rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.



            

Contact Data